EE200000512A - Erinevaid heterotsükliliste tuumade süsteeme sisaldavate 5-lipoksügenaasi inhibiitorite valmistamise protsess - Google Patents

Erinevaid heterotsükliliste tuumade süsteeme sisaldavate 5-lipoksügenaasi inhibiitorite valmistamise protsess

Info

Publication number
EE200000512A
EE200000512A EEP200000512A EEP200000512A EE200000512A EE 200000512 A EE200000512 A EE 200000512A EE P200000512 A EEP200000512 A EE P200000512A EE P200000512 A EEP200000512 A EE P200000512A EE 200000512 A EE200000512 A EE 200000512A
Authority
EE
Estonia
Prior art keywords
preparation
heterocyclic ring
ring systems
containing different
lipoxygenase inhibitors
Prior art date
Application number
EEP200000512A
Other languages
English (en)
Inventor
Norris Timothy
Francis Lambert John
Elizabeth Hnatow Megan
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200000512A publication Critical patent/EE200000512A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200000512A 1999-08-31 2000-08-31 Erinevaid heterotsükliliste tuumade süsteeme sisaldavate 5-lipoksügenaasi inhibiitorite valmistamise protsess EE200000512A (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15161599P 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
EE200000512A true EE200000512A (et) 2001-04-16

Family

ID=22539529

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000512A EE200000512A (et) 1999-08-31 2000-08-31 Erinevaid heterotsükliliste tuumade süsteeme sisaldavate 5-lipoksügenaasi inhibiitorite valmistamise protsess

Country Status (33)

Country Link
US (1) US6346624B1 (et)
EP (1) EP1081143A1 (et)
JP (1) JP2001106682A (et)
KR (1) KR20010050256A (et)
CN (1) CN1286250A (et)
AP (1) AP2000001910A0 (et)
AU (1) AU5360300A (et)
BG (1) BG104731A (et)
BR (1) BR0003945A (et)
CA (1) CA2317097A1 (et)
CZ (1) CZ20003158A3 (et)
EA (1) EA200000801A1 (et)
EE (1) EE200000512A (et)
GT (1) GT200000142A (et)
HR (1) HRP20000564A2 (et)
HU (1) HUP0003439A3 (et)
ID (1) ID27129A (et)
IL (1) IL138087A0 (et)
IS (1) IS5603A (et)
MA (1) MA26751A1 (et)
NO (1) NO20004313L (et)
NZ (1) NZ506632A (et)
OA (1) OA11452A (et)
PA (1) PA8499701A1 (et)
PE (1) PE20010520A1 (et)
PL (1) PL342281A1 (et)
SG (1) SG87146A1 (et)
SK (1) SK12872000A3 (et)
SV (1) SV2002000159A (et)
TN (1) TNSN00177A1 (et)
TR (1) TR200002529A2 (et)
UY (1) UY26314A1 (et)
ZA (1) ZA200004435B (et)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6669042B1 (en) * 2002-09-30 2003-12-30 Hewlett-Packard Development Company, L.P. Integrated positioning and locking device
EP1834953A1 (en) * 2006-03-14 2007-09-19 Ranbaxy Laboratories Limited Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063928A (en) * 1994-10-18 2000-05-16 Pfizer Inc 5-lipoxygenase inhibitors
US5883106A (en) * 1994-10-18 1999-03-16 Pfizer Inc. 5-lipoxygenase inhibitors
SK281577B6 (sk) 1994-10-18 2001-05-10 Pfizer Inc. Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze
US6239285B1 (en) * 1998-02-06 2001-05-29 Pfizer Inc Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems

Also Published As

Publication number Publication date
TR200002529A2 (tr) 2001-04-20
PE20010520A1 (es) 2001-04-28
BG104731A (en) 2001-09-28
HUP0003439A3 (en) 2002-08-28
SV2002000159A (es) 2002-01-23
IL138087A0 (en) 2001-10-31
CA2317097A1 (en) 2001-02-28
HU0003439D0 (en) 2000-08-30
SG87146A1 (en) 2002-03-19
OA11452A (en) 2003-12-08
SK12872000A3 (sk) 2001-11-06
CZ20003158A3 (cs) 2001-09-12
PA8499701A1 (es) 2001-12-14
GT200000142A (es) 2002-02-19
NO20004313L (no) 2001-03-01
MA26751A1 (fr) 2004-12-20
CN1286250A (zh) 2001-03-07
JP2001106682A (ja) 2001-04-17
US6346624B1 (en) 2002-02-12
EP1081143A1 (en) 2001-03-07
TNSN00177A1 (fr) 2005-11-10
AP2000001910A0 (en) 2000-09-30
HRP20000564A2 (en) 2001-12-31
ID27129A (id) 2001-03-01
BR0003945A (pt) 2001-04-03
HUP0003439A2 (hu) 2001-08-28
EA200000801A1 (ru) 2001-04-23
IS5603A (is) 2001-03-01
UY26314A1 (es) 2001-04-30
KR20010050256A (ko) 2001-06-15
PL342281A1 (en) 2001-03-12
ZA200004435B (en) 2002-02-28
NO20004313D0 (no) 2000-08-30
NZ506632A (en) 2002-02-01
AU5360300A (en) 2001-03-08

Similar Documents

Publication Publication Date Title
EE200200183A (et) Meetod polüisobuteenfenooli sisaldavate Mannichi aduktide saamiseks
NO20025186L (no) Fremgangsmåte for syntese av en ecteinascidinforbindelse
IS2223B (is) Aðferð til framleiðslu á 5-sýanóþalíði
NO20013569D0 (no) Fremgangsmåte ved fremstilling av L-fenylephrine-hydroklorid
NO20022123D0 (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
FI990509A (fi) Häiriönpoistomenetelmä
EE200000513A (et) Erinevaid heterotsükliliste tuumade süsteeme sisaldavate 5-lipoksügenaasi inhibiitorite valmistamise protsess
NO20020059L (no) Fremgangsmåte for fremstilling av dibenzotiazepinderivater
EE200000512A (et) Erinevaid heterotsükliliste tuumade süsteeme sisaldavate 5-lipoksügenaasi inhibiitorite valmistamise protsess
NO20013407L (no) Fremgangsmate for fremstilling av kinolinkarbaldehyd
NO20013995D0 (no) Fremgangsmate for fremstilling av L-sorbose
NO20024887L (no) FremgangsmÕte for fremstilling av benzokondenserte heterosykliske forbindelser
NO20014383D0 (no) Fremgangsmåte for fremstilling av syklo-(Asp-DPhe-NMeVal-Arg- Gly)
DE60000817D1 (de) Calixaren-derivate für extraktion von aktiniden
NO20022956D0 (no) Fremgangsmåte for fremstilling av nitroguanidin
NO20000805L (no) FremgangsmÕte for fremstilling av organiske azider
NO20001985L (no) FremgangsmÕte for forming av strimmelformede folier
HU0003438D0 (en) Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
NO20020327D0 (no) Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol
NO20021788D0 (no) Fremgangsmåte for fremstilling av ulcerterapeutika
NO20022671D0 (no) Fremgangsmåte for fremstilling av tienopyrimidiner
NO20002558D0 (no) FremgangsmÕte for fremstilling av findisperse eksplosivstoffer
NO20014451D0 (no) Fremgangsmåte for fremstilling av tiazolidinderivater
GB9906120D0 (en) Process for the preparation of new heterocyclic compounds